Cardiac function of myocardial infarction rat models and NSF-siRNA, a key protein released from vesoactive substance

doi:10.3969/j.issn.2095-4344.2014.27.005

Abstract

Abstract:

BACKGROUND: How to reduce the incidence and mortality of cardiovascular diseases is an urgent concern in the field of public health.
OBJECTIVE: To explore the influence of adenovirus-mediated NSF-siRNA release from vesoactive substance on the cardiac function of a rat model of myocardial infarction.
METHODS: A total of 36 adult Sprague-Dawley rats were applied to establish acute myocardial infarction models by ligating the anterior descending branch of the left coronary artery. After the model was determined by electrocardiogram successfully, NSF-siRNA adenovirus (experimental group), negative adenovirus (control group) and normal saline (normal saline group) were injected near the infarct area of the left ventricle of rats respectively. After 2 weeks, the left ventricular ejection fraction (LVEF) was tested with noninvasive ultrasonic cardiogram. Meanwhile, the left ventricular end-diastolic pressure (LVEDP) and maximum pressure rising speed of left ventricular (dp/dt max) were detected by connecting the right external carotid artery place pipe to the BL-420 biological function experiment system, to evaluate the cardiac function. Subsequently, the rat heart was harvested for serial sections to observe the infarcts range.
RESULTS AND CONCLUSION: After 2 weeks, the LVEF of the experimental group was increased remarkably (P < 0.05), while the LVEDP of the experimental group was decreased evidently compared with the control group and normal saline group (P < 0.05), and the dp/dt max of the experimental group was significantly increased (P < 0.05). Furthermore, there were no significant differences in the infarct area among groups (P > 0.05). The local injection of adenovirus mediated NSF-siRNA expression vector in infarct part can improve the cardiac function indexes, including LEVF, LVEDP and dp/dt max 2 weeks after myocardial infarction, but it has no impact on the myocardial infarction area.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: myocardial infarction, models, animal, stroke volume, RNA interference

CLC Number:

R318

Liu Yan, Zhou Yong, Yang Shui-xiang, Wang Zhen. Cardiac function of myocardial infarction rat models and NSF-siRNA, a key protein released from vesoactive substance[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(27): 4287-4292.

Figures/Tables 1

References

[1]Into T, Kanno Y, Dohkan J,et al.Pathogen recognition by Toll-like receptor 2 activates Weibel-Palade body exocytosis in human aortic endothelial cells.J Biol Chem. 2007;282(11):8134-8141.
[2]Yamakuchi M, Kirkiles-Smith NC, Ferlito M,et al.Antibody to human leukocyte antigen triggers endothelial exocytosis.Proc Natl Acad Sci U S A. 2007;104(4):1301-1306.
[3]Lowenstein CJ, Tsuda H. N-ethylmaleimide-sensitive factor: a redox sensor in exocytosis.Biol Chem. 2006;387(10-11):1377-1383.
[4]Lowenstein CJ, Morrell CN, Yamakuchi M.Regulation of Weibel-Palade body exocytosis.Trends Cardiovasc Med. 2005;15(8):302-308.
[5]Yang SX, Yan J, Deshpande SS,et al.Rac1 regulates the release of Weibel-Palade Bodies in human aortic endothelial cells.Chin Med J (Engl). 2004;117(8):1143-1150.
[6]杨水祥,魏晓菲,崔淯夏,等.RNA干扰抑制内皮细胞韦伯潘力氏小体的释放[J].中华老年心脑血管病杂志,2012,14(6): 630-634.
[7]Ming X.Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.Expert Opin Drug Deliv. 2011;8(4):435-449.
[8]吕铁伟,田杰,江德勤,等.急性心肌梗塞动物模型的建立[J].中国比较医学杂志,2004,14(3):166-169.
[9]Sioud M.Promises and challenges in developing RNAi as a research tool and therapy.Methods Mol Biol. 2011;703:173-187.
[10]Shimizu H, Fujita T.New short interfering RNA-based therapies for glomerulonephritis. Nat Rev Nephrol. 2011; 7(7):407-415.
[11]Burnett JC, Rossi JJ, Tiemann K.Current progress of siRNA/shRNA therapeutics in clinical trials.Biotechnol J. 2011; 6(9):1130-1146.
[12]Tesz GJ, Aouadi M, Prot M,et al.Glucan particles for selective delivery of siRNA to phagocytic cells in mice.Biochem J. 2011; 436(2):351-362.
[13]Jeong JH, Kim SH, Lee M,et al.Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice.J Control Release. 2010;143(1):88-94.
[14]Janson CG, Romanova LG, Leone P,et al.Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease. Neurosurgery. 2014;74(1):99-111.
[15]Hsu PY, Yang YW.Gene delivery via the hybrid vector of recombinant adeno-associated virus and polyethylenimine. Eur J Pharm Sci. 2014;52:62-68.
[16]DeVincenzo J, Lambkin-Williams R, Wilkinson T,et al.A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.Proc Natl Acad Sci U S A. 2010;107(19):8800-8805.
[17]Matsushita K, Morrell CN, Mason RJ,et al.Hydrogen peroxide regulation of endothelial exocytosis by inhibition of N-ethylmaleimide sensitive factor.J Cell Biol. 2005;170(1):73-79.
[18]Cipriano DJ, Jung J, Vivona S,et al.Processive ATP-driven substrate disassembly by the N-ethylmaleimide-sensitive factor (NSF) molecular machine.J Biol Chem. 2013;288(32): 23436-23445.
[19]Lowenstein CJ, Morrell CN, Yamakuchi M.Regulation of Weibel-Palade body exocytosis.Trends Cardiovasc Med. 2005;15(8):302-308.
[20]Morrell CN, Matsushita K, Lowenstein CJ. A novel inhibitor of N-ethylmaleimide-sensitive factor decreases leukocyte trafficking and peritonitis.J Pharmacol Exp Ther. 2005;314(1):155-161.
[21]Liu Y, Cheng K, Gong K,et al.Pctaire1 phosphorylates N-ethylmaleimide-sensitive fusion protein: implications in the regulation of its hexamerization and exocytosis.J Biol Chem. 2006;281(15):9852-9858.